Archives
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2018-07
-
MicroRNAs miRNAs are endogenous small RNA molecules nucleoti
2021-10-14

MicroRNAs (miRNAs) are endogenous small RNA molecules 20–25 nucleotides in length; they regulate multiple genes by binding to target mRNAs, thereby controlling the stability and translation of protein coding mRNAs (Esteller, 2011, Guo et al., 2010). It has been established that betaxolol receptor o
-
br Introduction It is well known
2021-10-14

Introduction It is well known that conventional cancer treatment strategies, such as surgery, radiotherapy, and chemotherapy all have their own limitations, which lead to an unsatisfactory therapeutic effect. Under this situation, the combination of two or more therapeutic strategies has recently
-
Acknowledgments The authors would like to thank
2021-10-14

Acknowledgments The authors would like to thank members of the Department of Discovery Synthesis (DDS) and Biocon-Bristol Myers Squibb Research Center (BBRC) for scaling up key intermediates, analytical team for analytical experiments, lead profiling group for evaluating compounds in an in vitro AD
-
Lastly the N position of this privileged
2021-10-14

Lastly, the N-1 position of this privileged pyrimidone was further substituted by a variety of different aromatic, aliphatic or heteroaromatic linkers with carbonyl functionality. In this task, different N-1 substituted pyrimidones 20i–20xiv were generated and check against HIV IN 3′-processing and
-
The histamine H receptor H R amino acids is located
2021-10-14

The histamine H3 receptor (H3R; 326–445 amino-acids) is located on histaminergic neuron somata, dendrites and axon varicosities, as well as on the axon varicosities and somata of other neurons, providing negative feedback to inhibit histamine synthesis and the release of histamine or other transmitt
-
The presence of the H receptor in
2021-10-14

The presence of the H3 receptor in humans was confirmed approximately 25 years ago, and the receptor was successfully cloned in 1999 (Thurmond, 2010). The H3 receptor is unique, as it controls feedback of histamine release, particularly in the central nervous system, where it modulates neurotransmit
-
Since its development the HCV replicon system Lohmann
2021-10-14

Since its development, the HCV replicon system (Lohmann et al., 1999) has been a critical tool in the HCV antiviral discovery process (Gottwein et al., 2009, Imhof and Simmonds, 2010, Lohmann et al., 1999, Pietschmann et al., 2001, Imhof and Simmonds, 2010, Gottwein et al., 2009). The replicon assay
-
FOLE was recently approved for use in
2021-10-14

FOLE was recently approved for use in PN-dependent patients in the United States. However, potential adverse effects of FOLE, including bleeding risk, and effects on the immune system [8], [39], render its use in certain patient populations controversial. Identification of key downstream modulators
-
Extensive pharmacological and structural analysis shows GCGR
2021-10-14

Extensive pharmacological and structural analysis shows GCGR antibody REMD-477 competitively blocks GLC binding to the GCGR with 30-pM binding affinity, and can fully inhibit the receptor activity at low nanomolar concentrations in Doxycycline HCl 14, 17, 20. Functionally identical to REMD-477, REMD
-
When PKC was applied alone it attenuated the activity run
2021-10-14

When PKC19–31 was applied alone, it attenuated the activity run-down following excision. Furthermore, the activity induced by addition of PKC19–31 during PMA treatment in many cases was higher than in controls. Accordingly, in our experimental conditions, the mechanism which underlays channel inhibi
-
By using pharmacological treatment with CBX or
2021-10-14

By using pharmacological treatment with CBX or transgenic animals lacking the two major astroglial Cxs, the Double KO mouse, we demonstrated that the gap-FRAP technique was able to detect the total inhibition of GJC with a reduction of about 39% and 38% compared to control, respectively. The residua
-
br Materials and methods br Results br Discussion
2021-10-14

Materials and methods Results Discussion The current study validates a key role for GAL3 receptors in consummatory drive for sucrose, saccharin, and most notably ethanol intake in mice. We show that alcohol preferring mice drink less ethanol compared to wildtype mice when treated with the G
-
br Acknowledgements Research was funded by
2021-10-13

Acknowledgements Research was funded by the Natural Sciences and Engineering Council of Canada (NSERC) (Grant #210290) SGF. The funding body played no role in the design or execution of the study. The authors declare no conflict of interest. Introduction HBO2 therapy is the use of 100% oxygen
-
In early a collaborative effort between the group that
2021-10-13

In early 2017, a collaborative effort between the group that pioneered the above described evidence of platinum-induced PUFA chemotherapy resistance and a group that has contributed to much of the known molecular pharmacology of FFA4, revealed that the molecular target of 16:4(n-3), which affords ch
-
Nogo-66 (1-40) sale Initially the synthesized compounds from
2021-10-13

Initially, the synthesized compounds from were evaluated for human GSNOR potency before generating additional SAR in order to understand scaffold feasibility and required functionality as illustrated in . Commercially available 4′-hydroxy-[1,1′-biphenyl]-4-carboxylic Nogo-66 (1-40) sale having si
15390 records 598/1026 page Previous Next First page 上5页 596597598599600 下5页 Last page